Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 12, pp 2433–2440 | Cite as

Progress in gene therapy using oncolytic vaccinia virus as vectors

  • Xue Yang
  • Biao Huang
  • Lili Deng
  • Zhigang Hu
Review – Clinical Oncology
  • 244 Downloads

Abstract

Background

Vaccinia virus was widely used in the World Health Organization’s smallpox eradication campaign and is currently a promising vector for gene therapy owing to its unique characteristics. Vaccinia virus can selectively replicate and propagate productively in tumor cells, resulting in oncolysis. In addition, rapid viral particle production, wide host range, large genome size (approximately 200 kb), and safe handling render vaccinia virus a suitable vector for gene therapy.

Materials and methods

Cancer vaccines and gene therapy are being studied in clinical trials and experiment researches. However, we put forward unique challenges of optimal selection of foreign genes, administration and modification of VACV, personalized medicine, and other existing problems, based on current researches and our own experiments.

Conclusion

This review presents an overview of the vaccinia virus from its mechanisms to medical researches and clinical trials. We believe that the solution to these problems will contribute to understanding mechanisms of VACV and provide a theoretical basis for clinical treatment.

Keywords

Oncolytic viruses Vaccinia virus Cancer vaccines Gene therapy Oncolytic vector 

Abbreviations

VACV

Vaccinia virus

WR

Western reserve

VTT

Vaccinia virus Tian Tan strain

TK

Thymidine tyrosine kinase

GM–CSF

Granulocyte–macrophage colony stimulating factor

MVA

Modified vaccinia Ankara

CD

Cytosinedeaminase

5-FU

5-fluorouracil

RNAi

RNA interference

siRNA

Short interfering double-stranded RNA

shRNA

Short hairpin RNA

Notes

Acknowledgements

We thanked Jie Liu for the literature search.

Author contributions

XY and BH did the data analysis and interpretation, and manuscript writing; LD did collection and assembly of data; ZH did the conception/design, provision of study material or patients, and final approval of manuscript.

Funding

This study was supported by National Natural Science Foundation of China (81703061).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This manuscript does not contain any studies with human participants performed by any of the authors.

References

  1. Bartlett DL, Liu Z, Sathaiah M et al (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12(1):103CrossRefGoogle Scholar
  2. Bennink JR, Yewdell JW, Smith GL et al (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311(5986):578–579CrossRefGoogle Scholar
  3. Breitbach CJ, Burke J, Jonker D et al (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362):99–102CrossRefGoogle Scholar
  4. Chalikonda S, Kivlen MH, O’Malley ME et al (2008) Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15(2):115–125CrossRefGoogle Scholar
  5. Chan WM, Mcfadden G (2014) Oncolytic poxviruses. Ann Rev Virol 1(1):119Google Scholar
  6. Clark R, Kenyon J, Bartlett N et al (2006) Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87(1):29–38CrossRefGoogle Scholar
  7. Clercq ED (2010) Historical perspectives in the development of antiviral agents against poxviruses. Viruses 2(6):1322–1339CrossRefGoogle Scholar
  8. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823.  https://doi.org/10.1126/science.1231143 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Deng L, Fan J, Guo M et al (2016) Oncolytic and immunologic cancer therapy with GM–CSF-armed vaccinia virus of Tian Tan strain Guang9. Cancer Lett 372(2):251CrossRefGoogle Scholar
  10. Downscanner S, Zong SG, Ravindranathan R et al (2016) Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther J Am Soc Gene Ther 24(8):1492–1501CrossRefGoogle Scholar
  11. Fend L, Remy-Ziller C, Foloppe J et al (2016) Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment. Oncoimmunology 5(2):e1080414CrossRefGoogle Scholar
  12. Foloppe J, Kintz JN, Findeli A et al (2008) Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 15(20):1361CrossRefGoogle Scholar
  13. Fu G, Lin XQ, Fan Y et al (2005) RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol Ther 4(8):822–829CrossRefGoogle Scholar
  14. Fukuhara H, Ino Y, Todo T (2016) Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 107(10):1373–1379CrossRefGoogle Scholar
  15. Garber DA, O’Mara LA, Gangadhara S et al (2012) Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86(23):12605–12615CrossRefGoogle Scholar
  16. Guo ZS, Bartlett DL (2014) Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 21(7):261–263CrossRefGoogle Scholar
  17. Guse K, Cerullo V, Hemminki A (2011) Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 11(5):595–608CrossRefGoogle Scholar
  18. Henderson DA (1988) Smallpox and its eradication. World Health Organization, GenevaGoogle Scholar
  19. Hengstschläger M, Knöfler M, Müllner EW et al (1994) Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 269(19):13836–13842PubMedGoogle Scholar
  20. Hensbergen PJ, Wijnands PG, Schreurs MW et al (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8 + T lymphocytes but not inhibition of angiogenesis. J Immunother 28(4):343CrossRefGoogle Scholar
  21. Heo J, Reid T, Ruo L et al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19(3):329–336CrossRefGoogle Scholar
  22. Hou W, Sampath P, Rojas JJ et al (2016) Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer Cell 30(1):108–119CrossRefGoogle Scholar
  23. Izutsu T, Konda R, Sugimura J et al (2011) Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma. J Urol 185(6):2353–2358CrossRefGoogle Scholar
  24. Kanegane C, Sgadari C, Kanegane H et al (1998) Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64(3):384–392CrossRefGoogle Scholar
  25. Kaufman HL, Flanagan K, Lee CS et al (2002) Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 20(13–14):1862–1869CrossRefGoogle Scholar
  26. Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642CrossRefGoogle Scholar
  27. Kim JH, Oh JY, Park BH et al (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM–CSF. Mol Ther 14(3):361–370CrossRefGoogle Scholar
  28. Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64–71CrossRefGoogle Scholar
  29. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7(7):781–787CrossRefGoogle Scholar
  30. Kirn DH, Wang Y, Boeuf FL et al (2007) Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. Plos Med 4(12):e353CrossRefGoogle Scholar
  31. Kwa S, Lai L, Gangadhara S et al (2014) CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88(17):9579–9589CrossRefGoogle Scholar
  32. Laure A (2016) Oncolytic viruses as immunotherapy: progress and remaining challenges. Oncotargets Ther 9:2627Google Scholar
  33. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323–331CrossRefGoogle Scholar
  34. Li J, O’Malley M, Urban J et al (2011) Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther J Am Soc Gene Ther 19(4):650–657CrossRefGoogle Scholar
  35. Liu S, Dai M, You L et al (2013) Advance in herpes simplex viruses for cancer therapy. Sci China 56(4):298–305CrossRefGoogle Scholar
  36. Liu Z, Ravindranathan R, Li J et al (2016) CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology 5(3):e1091554CrossRefGoogle Scholar
  37. Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79(23):7415–7419CrossRefGoogle Scholar
  38. Mccart JA, Ward JM, Lee J et al (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 1(24):8751–8757Google Scholar
  39. Newman W, Southam CM (1954) Virus treatment in advanced cancer; a pathological study of fifty-seven cases. Cancer 7(1):106–118CrossRefGoogle Scholar
  40. Okoli A, Okeke MI, Tryland M et al (2018) CRISPR/Cas9—advancing orthopoxvirus genome editing for vaccine and vector development. Viruses 10(1):50CrossRefGoogle Scholar
  41. Parato KA, Breitbach CJ, Boeuf FL et al (2012) The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20(4):749CrossRefGoogle Scholar
  42. Pearce L, Rivers TM (1927) Effect of host immunity to a filterable virus (virus III) on the growth and malignancy of a transplantable rabbit neoplasm. J Exp Med 46(1):65–80CrossRefGoogle Scholar
  43. Rojas JJ, Thorne SH (2012) Theranostic potential of oncolytic vaccinia virus. Theranostics 2(4):363–373CrossRefGoogle Scholar
  44. Scholl SM, Balloul JM, Le GG et al (2000) Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23(5):570CrossRefGoogle Scholar
  45. Shen Y, Nemunaitis J (2005) Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther J Am Soc Gene Ther 11(2):180–195CrossRefGoogle Scholar
  46. Southam CM, Moore AE (1952) Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5(5):1025–1034CrossRefGoogle Scholar
  47. Suryawanshi YR, Zhang T, Essani K (2017) Oncolytic viruses: emerging options for the treatment of breast cancer. Med Oncol 34(3):43CrossRefGoogle Scholar
  48. Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3(3):263–271CrossRefGoogle Scholar
  49. Sze DY, Reid TR, Rose SC (2013) Oncolytic virotherapy. J Vasc Interv Radiol 24(8):1115–1122CrossRefGoogle Scholar
  50. Thorne SH (2011) Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 50(2–3):286–293CrossRefGoogle Scholar
  51. Thorne SH, Hwang TH, O’Gorman WE et al (2007) Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Investig 117(11):3350CrossRefGoogle Scholar
  52. Walker JD, Sehgal I, Kousoulas KG (2011) Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol 85(14):7363CrossRefGoogle Scholar
  53. Wang Y, Zhu H, Quan L et al (2005) Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther 4(9):974–978CrossRefGoogle Scholar
  54. Wang B, Yan X, Guo Q et al (2015) Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain. Oncotarget 6(18):16019–16030PubMedPubMedCentralGoogle Scholar
  55. Wang T, Yin H, Li Y et al (2017) Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes. Parasite J Soc Fr Parasitol 24:12Google Scholar
  56. Wyatt LS, Earl PL, Eller LA et al (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101(13):4590–4595CrossRefGoogle Scholar
  57. Yano J, Hirabayashi K, Nakagawa S et al (2004) Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10(22):7721CrossRefGoogle Scholar
  58. Yoo NJ, Kim HS, Kim SY et al (2003) Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. Apmis 111(4):382–388CrossRefGoogle Scholar
  59. Yu F, Wang X, Guo ZS et al (2014) T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther J Am Soc Gene Ther 22(1):102CrossRefGoogle Scholar
  60. Yuan M, Zhang W, Wang J et al (2015a) Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J Virol 89(9):5176–5179CrossRefGoogle Scholar
  61. Yuan M, Gao X, Chard LS et al (2015b) A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. Mol Ther Methods Clin Dev 2(C):15035CrossRefGoogle Scholar
  62. Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7(3):347–367CrossRefGoogle Scholar
  63. Zhang Q, Yu YA, Wang E et al (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Can Res 67(20):10038–10046CrossRefGoogle Scholar
  64. Zhang Q, Liang C, Yu YA et al (2009) The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genom 282(4):417–435CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Affiliated Wuxi People’s Hospital of Nanjing Medical UniversityWuxi Children’s HospitalWuxiChina
  2. 2.School of Life ScienceZhejiang Sci-Tech UniversityZhejiangChina
  3. 3.Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear MedicineJiangsu Institute of Nuclear MedicineWuxiChina

Personalised recommendations